Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
PC=Placebo An RCT of nondiabetic patients (N = 1961)1: After 68 weeks, mean weight loss was 15% (15 kg) versus 2% (3 kg) PC
We will tell you honestly what the science shows, what we don't yet know, and what we can offer with integrity and quality you can trust
In the SURPASS clinical trial programme evaluating tirzepatide, common gastrointestinal symptoms included nausea (reported in 12-24% of patients), diarrhoea (13-22%), vomiting (2-10%), and dyspepsia (indigestion)
Progress Is Not Linear Weight loss often occurs in phases
Individual Risk Profile: The potential cardiovascular benefits of tirzepatide will depend on an individuals specific risk factors, including their history of heart disease, diabetes status, blood pressure, and lipid levels
Ignoring new symptomsreport any unusual symptoms to our medical team promptly
